News coverage about Covance (NYSE:CVD) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Covance earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave news articles about the healthcare company an impact score of 45.6623954947133 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Covance (CVD) opened at $107.07 on Friday.
ILLEGAL ACTIVITY NOTICE: “Covance (NYSE:CVD) Earns Coverage Optimism Score of 0.22” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://stocknewstimes.com/2017/11/18/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-covance-cvd-stock-price.html.
Covance Company Profile
Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.
Receive News & Ratings for Covance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance Inc. and related companies with MarketBeat.com's FREE daily email newsletter.